Saccharomyces boulardii: Strains, Digestive Evidence and Safety

Key takeaways

  • Saccharomyces boulardii is a live probiotic yeast. The exact strain, viable count, preparation and clinical setting matter (Taxonomy; Strain and preparations).
  • Antibiotic-associated diarrhea is its most plausible digestive use, but positive pooled results sit alongside a publicly funded German null trial and incompletely disclosed studies (Favorable review; Public-funded null trial).
  • Preventing ordinary antibiotic-associated diarrhea, preventing a first C. difficile infection and preventing recurrence are different claims (Distinct clinical questions).
  • Small IBS studies found some quality-of-life or inflammatory-marker improvements without convincing relief of the main bowel symptoms; the key trials had commercial funding (QOL versus symptoms; Pilot outcomes and sponsor).
  • This is not a harmless option for everyone. Bloodstream yeast infection can occur, especially with critical illness, immunosuppression or central venous catheters (Original safety study; Contraindications).
  • A probiotic cannot replace rehydration, infection assessment or prescribed treatment. Current guidance does not support routine use for every episode of diarrhea (Pediatric recommendation; Adult CDI guidance).

Evidence verdict: Insufficient for a dependable general benefit under the strict financial screen used here. Positive and negative findings concern different preparations, populations and diarrhea definitions. The reviewed evidence does not establish a reliable, broadly applicable retail-product benefit for AAD, CDI prevention or recurrence, acute gastroenteritis, or IBS. This financial-screen verdict is separate from the certainty assigned by individual reviews. Confidence is high that strain identity and vulnerable-patient exclusions matter; it is low in a general product-specific benefit estimate. Pooled evidence; German trial; Recent positive trial; Safety action.

Contents

Evidence summary · What it is · Forms · Mechanism · Hype · Benefits · Verdicts · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Funding · Regulation · FAQs · Sources

Evidence summary

These are editorial benefit grades after the financial screen described below, rather than the clinical certainty assigned by the source reviews. Commercial and financially unresolved findings remain visible, including favorable results. A public grant or no-conflict declaration does not establish every underlying payment or product transaction.

Claim Human evidence Source Funding or conflict Strength after screening
Prevents antibiotic-associated diarrhea in adults Positive pooled literature; a large German trial found no advantage Szajewska 2015; Ehrhardt 2016 Mixed/unresolved pool; German trial used public funds and purchased product Insufficient for dependable general benefit (Review; German trial).
Prevents diarrhea in a recent hospital trial Large benefit reported in 100 adults, with an unusually high comparator event rate Kovacevic 2026 No external funding declared; placebo procurement unresolved Important positive context; independent replication needed (Bularen original).
Prevents antibiotic-associated diarrhea in children Favorable original abstract and pooled literature Kotowska 2005; 2019 review, partial access Complete original Kotowska methods, funding and procurement unavailable Insufficient under the strict financial screen
Prevents a first C. difficile episode A mixed-probiotic synthesis suggests a small benefit; yeast-specific evidence is less secure Cochrane 2025 Review reports no funding for update; underlying trials have varied provenance Insufficient for this yeast/product (Current review abstract) (Current original abstract).
Prevents C. difficile recurrence Older adjunct trials have subgroup signals McFarland 1994; Surawicz 2000 Biocodex-affiliated authorship Insufficient independent evidence (1994 original abstract; 2000 original relevant sections).
Shortens acute diarrhea Positive pediatric syntheses, but a purchased-product Italian trial was null for the yeast arm Canani 2007; McFarland and Li 2025 Canani declared no funding/conflicts; 2025 synthesis funded by Biocodex Inconsistent; insufficient independent general benefit (Italian original; Chinese review original).
Relieves IBS symptoms Quality-of-life signals with no convincing main bowel-symptom advantage Choi 2011; Abbas 2014 Kuhnil and Biocodex support, respectively Insufficient independent evidence (Korean original; Pakistani original).
Is safe in critically ill or catheterized patients Invasive infection reports and regulatory contraindications Rannikko 2021; EU safety action State/charity safety research with an indirect author tie; regulator assessment Clear reason to avoid these high-risk uses (Finnish original; Original EU safety action).

What it is

S. boulardii is a yeast used in live-microorganism products marketed for digestive health. Genomic research places it within the Saccharomyces cerevisiae lineage, despite the familiar separate name. This does not make a bakery yeast, brewer’s yeast, nutritional yeast or yeast-protein powder an interchangeable probiotic. A taxonomic relationship does not establish the same organism count, formulation or clinical effect. Khatri 2017 genomic study

CNCM I-745 is an important studied strain identifier. The EMA assessment links it with the CBS 5926 designation used in several medicines and older studies. That mapping should be documented for the product being discussed rather than presumed from the words “S. boulardii” alone. EMA strain and medicinal-product assessment

Oral survival is also different from permanent colonization. The regulated Bioflor information describes temporary passage through the digestive tract, with stool detection disappearing within days after discontinuation. That pharmacokinetic description does not prove durable microbiome repair. Bioflor product information

Forms and grades

Form or label What it establishes Important limitation
S. boulardii CNCM I-745, freeze-dried live cells A named strain and a preservation method Product-specific viable count and clinical indication still matter (Specified preparation).
S. cerevisiae Hansen CBS 5926 A designation used in medicinal-product research Confirm the documented identity and formulation rather than substituting any S. cerevisiae product (Recorded strain mapping).
CNCM I-1079 or another numbered strain A different strain designation Clinical results cannot automatically be borrowed from I-745/CBS 5926 (Strain-transfer assessment).
Species name without a strain An incomplete organism description It does not identify which trial findings apply (Identity requirement).
Capsules, sachets or a bacterial–yeast blend A delivery form or combination A blend’s result cannot isolate the yeast’s contribution (Intervention specificity).
Heat-killed yeast, yeast extract or nutritional yeast A different intervention Live-cell clinical trials do not establish its effect (Live-microorganism definition).

EFSA explicitly rejected an attempt to transfer evidence between CNCM I-1079 and Hansen CBS 5926 when identity had not been adequately demonstrated. Its 2012 opinion found the submitted evidence insufficient for the claimed defense against gastrointestinal pathogens. That is a specific claim assessment, not a finding that all S. boulardii products are useless. EFSA opinion

Milligrams measure material mass; colony-forming units, or CFU, estimate viable organisms under the assay conditions. They are not universally convertible. The relevant specification includes the strain, count, storage conditions, expiry and complete preparation. More CFU, more strains, a “clinical strength” label or a historical brand name does not establish superior patient outcomes (Mass and viable-count specifications; Product handling).

How it works

The assessment describes illustrative nonclinical research on toxins, pathogen adherence, secretion and inflammatory signaling. These are possible mechanisms, rather than established clinical outcomes. Yeast resistance to many antibacterial medicines does not mean resistance to antifungals or prevention of every antibiotic complication (2021 pharmacology assessment; Antifungal restriction).

A 2025 experiment used antibiotic-perturbed stool systems and human-derived cells or tissue, rather than treating diarrhea patients. Biocodex provided product and funding alongside public support; company employees and other commercial relationships were disclosed. Effects varied by antibiotic and dose and did not uniformly restore microbial composition. “Independently of the host” describes the experimental mechanism, not financial independence (Full original methods, results and disclosures).

Hype versus evidence

“Protects your gut during antibiotics” compresses several distinct questions. Does the preparation reduce any loose stools, a sustained episode of antibiotic-associated diarrhea, laboratory-confirmed C. difficile disease, hospitalization, or a recurrence after infection? A favorable answer to one does not establish the others (Separate outcomes and populations).

Similarly, a change in a cytokine, stool organism profile or laboratory barrier marker is not equivalent to less pain, less diarrhea, improved daily functioning or a durable cure. IBS research is a particularly clear example: some commercially supported studies reported biological or quality-of-life changes without superior bowel-symptom relief. Abbas original report

The phrases “natural,” “nonpathogenic” and “probiotic” should not be read as unconditional safety guarantees. An organism that is tolerated in many otherwise healthy participants can cause invasive infection in a vulnerable patient. The population exclusions in a trial are part of its safety interpretation (Vulnerable-group exclusions; Actual contraindications).

Benefits by claim

Adult antibiotic-associated diarrhea prevention Insufficient independent evidence for a dependable benefit

The overall literature is favorable. A 2015 S. boulardii-specific meta-analysis included 21 trials and 4,780 participants; across ages, diarrhea occurred in 8.5% of yeast recipients versus 18.7% of controls, with a pooled risk ratio of 0.47. Definitions, populations and study provenance varied. This is context for a plausible benefit, not a funding-cleared effect estimate or a guarantee for a particular bottle. The review was funded in full by the Medical University of Warsaw; Hania Szajewska declared speaking work for Biocodex. All underlying trial funding chains were not recovered. Szajewska and Kołodziej 2015

The publicly funded German SacBo trial randomized 477 adults and stopped for futility before the planned 1,520. It reported 21 AAD episodes among 246 yeast recipients versus 19 among 231 placebo recipients: HR 1.02 (95% CI 0.55–1.90). Episodes are not interchangeable with people affected. 185 diaries were incomplete; the null result remains imprecise. The trial used purchased Perenterol and excluded important vulnerable groups. Ehrhardt 2016 original methods, tables and disclosures.

The 2026 Bosnia and Herzegovina Bularen trial reported AAD in 4/51 versus 35/49 adults over 28 days. Its definition was two loose stools in 24 hours without the German trial’s duration requirement. It had no prospective registration or formal a priori power calculation; secondary analyses were exploratory without multiplicity correction. No external funding or conflicts were declared, but Abela Pharm made placebo with unspecified payment or contribution terms. The high 71.4% comparator event rate and large effect require replication. Complete original.

These trials cannot be combined informally by comparing their percentages: eligibility, diarrhea definitions and observation windows differ. Prevention also differs from treating diarrhea that has already developed. The present screen does not justify a universal rule to add S. boulardii to every antibiotic prescription (German design; Bularen design).

Children’s antibiotic-associated diarrhea Insufficient independent confirmation

Kotowska’s primary abstract reports 269 children randomized and 246 with outcomes. Defined AAD occurred in 4/119 yeast recipients versus 22/127 controls; all-cause diarrhea was a separate outcome. The result is encouraging, but this review did not recover complete original methods, numerical tables or financial/product statements. University affiliation alone establishes no funding clearance. Original abstract; Later review, partial access.

The pediatric pooled signal cannot erase that gap. Nor can the safety of trial participants establish safety in premature infants, immunocompromised children or children with vascular catheters. A child-specific clinical decision must account for the illness, dehydration risk, exact product and exclusions, rather than scaling down an adult research dose (Original pediatric population; Vulnerable-group contraindications; Child warning signs).

Prevention of an initial C. difficile infection Insufficient for a specific yeast preparation

C. difficile-associated diarrhea is a subset of antibiotic-associated illness. A reduction in nonspecific diarrhea does not show prevention of toxin-mediated infection. Some trials recorded very few or no C. difficile cases, leaving this outcome unresolved even when the AAD result was favorable. In the 2015 yeast-specific synthesis, the adult C. difficile result was not statistically significant. Szajewska 2015

The current primary abstract of the 2025 Cochrane update includes 47 trials/15,260 participants overall and 38 trials/13,179 in its CDAD analysis. Across different probiotics, CDAD was 1.6% versus 3.2% (RR 0.50, 95% CI 0.38–0.64; low certainty). Missing outcomes, mixed preparations and 28 industry-funded or affiliated trials limit interpretation. The official public page mixes current plain-language totals with older structured-result totals; those older estimates are not repeated here. Complete final review tables and individual declarations were not recovered. Current review summary and primary abstract (Current original abstract).

AGA’s 2020 guideline conditionally suggested specified probiotics, including S. boulardii, during antibiotics for CDI prevention using low-certainty evidence. Its 2026 adult CDI expert update advises against probiotics for initial or recurrent prevention. The latter is commissioned expert guidance without a formal systematic review or GRADE ratings. These documents differ in date, scope and method; the historic suggestion is not an uncontested current endorsement. Original 2020 guideline; 2026 primary record and disclosures.

C. difficile recurrence and active infection Insufficient independent evidence

The 1994 adjunct trial’s original abstract reports 124 adults. In the recurrent subgroup, recurrence was 34.6% with yeast versus 64.7% with placebo alongside antibiotics; the first-episode subgroup was not significantly different. Original affiliations identify a Biocodex affiliation. Complete original methods, tables and funding disclosures were not recovered, so the subgroup signal is retained with both commercial and access limits. It was not yeast monotherapy. Original abstract and affiliation.

A subsequent recurrent-disease trial found a signal only in a small high-dose-vancomycin subgroup. The antibiotic regimen was not itself randomly assigned, and the AGA technical review judged the evidence fragile. The original report includes Biocodex affiliation, reports a Laboratoires Biocodex grant, and states that the company randomized and packaged the blinded study products. These older results do not establish a reliable recurrence-prevention strategy in current care. Surawicz 2000, original report copy, AGA technical review

Preventing a first infection, preventing another episode after treatment, and treating active infection require separate evidence. This article supplies no basis for replacing prescribed C. difficile treatment with a supplement, or for adding a live yeast to a critically ill patient’s regimen (Clinical questions and limited trials; Vulnerable-group contraindications).

Acute infectious diarrhea in children and adults Insufficient independent general benefit

Canani’s six-arm trial enrolled 571 children aged 3–36 months. Parents purchased assigned products; observers were blinded but parents were not. The 91-child historical Codex yeast arm did not significantly outperform the 92-child oral-rehydration arm for diarrhea duration, frequency or consistency. No funding/conflicts or pharmaceutical/food-company sponsorship were declared. Label contents were not independently assayed. Complete original methods, tables and disclosures.

McFarland and Li’s 2025 review included ten Chinese trials with 1,125 children, mostly hospitalized young children. All trials were unblinded without placebo; nine had some risk-of-bias concerns and one high risk. Positive results included duration and cure outcomes, with substantial heterogeneity and a publication-bias signal. Its SMD−1.63 is unitless despite the paper’s “days” label and cannot be translated into days saved. Biocodex funded research/publication; author commercial consultancy and advisory roles were disclosed. Complete underlying trial finances were not independently recovered. Full original review.

WHO’s 2024 guideline conditionally suggests against probiotics for acute watery diarrhea in children up to 10 years, with low-certainty evidence. It makes no recommendation for persistent diarrhea because of a knowledge gap. This broad recommendation is not a yeast-specific comparative trial. The original recommendation text was read, but the complete guideline methods and financial declarations were not recovered (Guideline; Original recommendation record).

The Thai report published in 2026 describes a 2016–18 open-label study: 72 hospitalized adults randomized, 71 analyzed after a yeast recipient died from worsening sepsis on day 2. Bioflor 250 mg twice daily for 5 days gave no additional stool-weight, frequency or consistency benefit over usual care. No funding was declared, but DKSH Thailand and Farmaline supported study drugs. The small trial does not provide general safety reassurance, and it did not establish that yeast caused the death. Original methods, results and disclosures.

IBS pain, diarrhea and quality of life Insufficient independent evidence

Choi’s Korean IBS-D/mixed trial randomized 90 people (45 per arm), then analyzed 67 completers (34/33), despite the abstract describing 67 as randomized. At 4 weeks, the primary IBS-QOL percent improvement was 15.4% versus 7.0% (p=0.03). Secondary bowel-symptom, stool-frequency and consistency outcomes were not superior. Kuhnil partly funded the trial; product purchase/donation terms were unstated. Attrition and the short, selected population limit inference. Complete original main paper and tables.

Abbas’s IBS-D pilot randomized 72 people and had 64 completers, using last observation carried forward. Yeast 750 mg/day or placebo for 6 weeks was added to ispaghula in both groups. Sample size was arbitrary without formal power calculation. Cytokine, selected histological and QOL changes did not establish an overall between-group bowel-symptom advantage; abdominal pain improved more with placebo. Biocodex supplied both yeast and matching placebo and a research grant. Full original methods, tables and declarations.

These are small, short studies in selected IBS populations. They do not establish effectiveness for constipation-predominant IBS, long-term symptom control or an unspecified “leaky gut” diagnosis. Quality of life is valuable, but it must be reported separately from pain and bowel-function outcomes (Short selected IBS trial; IBS-D pilot).

Permanent microbiome repair, Candida cleansing and general gut healing Insufficient

There is no independent clinical basis in this reviewed evidence for those broad promises. Laboratory effects on Candida, toxins or microbial metabolism are hypotheses about mechanisms. They cannot establish eradication of a diagnosed infection, permanent colonization or a general cure for chronic digestive symptoms. This is a limit on the claims supported here, not a claim that every proposed disease use has been exhaustively tested (Candida laboratory study; Microbiome laboratory study; Transient passage).

What works and what does not

Practical claim Verdict Why
A particular live-yeast preparation may reduce AAD in some settings Plausible; uncertain independent benefit Positive literature, heterogeneous results and funding gaps (Pooled findings; German trial; Recent positive trial).
Everyone taking antibiotics should use it Not established Trial populations and baseline risks differ (Different settings; Different endpoint).
Fewer loose stools proves C. difficile prevention Unsupported inference Different outcome and diagnostic requirements (Separate AAD/CDAD outcomes).
A recurrence signal proves it treats active C. difficile alone Unsupported Older trials used concurrent antibiotics (Adjunct original abstract; Adjunct trial).
IBS cytokine changes prove symptom relief Unsupported Mechanistic and patient-centered results diverged (Actual symptom and biological results).
Any S. boulardii strain or generic yeast works the same Unsupported Strain and preparation identity matter (Strain substantiation).
No serious event in a small trial proves safety in intensive care Unsafe inference Rare harms and excluded vulnerable groups require other evidence (Contraindications; Hospital cases).

Risks and side effects

Aspect Finding Source
Digestive tolerance The examined product information lists constipation Ultra-Levure label
Allergy and excipients Product information lists allergic reactions, including potentially severe reactions; this capsule contains lactose and sucrose Specific 50 mg capsule label
Vulnerable patients Invasive yeast infection is a concern in the contraindicated populations EU safety action

A label for one product does not describe every brand. The risk profile includes excipients as well as the yeast (Exact excipients; Different preparation).

Rannikko’s Finnish hospital study found documented recent S. boulardii use in at least 20 of 46 Saccharomyces fungemia cases. Ten cases lacked medication records and were classified as nonusers, making this a minimum count. Compared with same-ward bacteremia/candidemia controls, the association was OR 14 (95% CI 4–44). It lacks a denominator of all probiotic users and paired genetic strain matching, so cannot estimate a consumer’s absolute risk or attribute every case to a supplement. Full original safety study.

Roy’s seven-case Indian hospital series found recent probiotic use in six cases and close molecular similarity in three matched blood/product pairs. It includes a tiny local hospital cohort, but cannot estimate general consumer incidence. ICMR supported molecular typing and susceptibility work at PGIMER; no separate conflict declaration or product payment terms were reported in the inspected original. The matching provides microbiological corroboration alongside observational limits. Original relevant methods, results and acknowledgment; Primary metadata.

European regulators added contraindications for critically ill or immunocompromised patients, alongside central-venous-catheter restrictions. They also warn about contamination during capsule or sachet handling, including exposure of nearby patients who are not taking the product. Some reported outcomes were fatal. EU safety communication, Belgian regulator explanation

Safety note: New confusion, breathing difficulty, marked shivering or rapid deterioration with a suspected infection requires immediate medical assessment. Fever during live-yeast use is especially concerning in someone with immune suppression, critical illness or a vascular catheter. Bloody diarrhea needs prompt medical assessment; severe persistent abdominal pain, significant dehydration, vomiting blood or black tarry stools need urgent assessment. These symptoms should not be dismissed as “die-off” or evidence that a probiotic is working. NIDDK bleeding guidance. NHS sepsis guidance, NIDDK diarrhea warning signs

Interactions and important gaps

Substance or condition Mechanism or concern Severity/status Source
Oral or systemic antifungal medicine May inactivate the live yeast Label advises against co-administration; do not stop an indicated antifungal to accommodate a probiotic Bioflor label
Immunosuppressive treatment, chemotherapy or transplant care Invasive-infection concern in immunocompromised patients Suitability contraindication, not merely a timing interaction EU safety action
Central venous catheter Potential bloodstream entry or handling contamination Contraindicated; spacing does not solve the risk EU safety action
Very hot liquids, alcohol or unsuitable storage Can affect viability and product integrity Handling restriction; follow the exact preparation’s label Bioflor label
Other medicines and combination supplements Complete compatibility and long-term safety are not established for every product Unknown; absence of a known interaction is not comprehensive clearance Evidence gap in the reviewed sources (Finite label scope; Selected trial population).

The antifungal and handling restrictions are documented in Bioflor’s regulated product information. “Antibiotic-resistant yeast” should not be interpreted as resistance to all antimicrobial medicines or as protection against all antibiotic complications. Bioflor label

Pregnancy and breastfeeding evidence is limited. The French label advises avoiding pregnancy use as a precaution, while Bioflor advises avoiding use while breastfeeding. Product-specific restrictions matter. Short selected trials do not establish the safety of long-term daily use or use with seriously impaired gut integrity (Pregnancy precaution; Breastfeeding precaution; Impaired-gut caution).

Who should avoid self-treatment

The strongest exclusions are critical illness, immunocompromise and central venous catheters. Hospital use requires infection-control judgment that cannot be replaced by a supplement’s marketing. Handling matters for surrounding vulnerable patients too. European safety action

People with yeast allergy, relevant excipient allergies, significant gastrointestinal disease or impaired gut integrity need particular caution. Pregnancy, breastfeeding, infants and children require product- and situation-specific review. The age limit on one capsule may also reflect choking risk, rather than a biological threshold applicable to every sachet (Product restrictions; Capsule age/choking risk; Impaired-gut caution).

Recurrent diarrhea, weight loss, blood in the stool, significant dehydration or illness after antibiotics deserves assessment of its cause. Trying repeated probiotic brands can delay identification of an infection or another condition. NIDDK symptom guidance

Dosage and how it was taken in research

These are research exposures, not dosing recommendations. A regimen can appear in this table even when the trial was null, commercially supported or incompletely disclosed.

Research setting Studied preparation or exposure Duration Interpretation
German adult AAD prevention Perenterol forte 250 mg twice daily During antibiotics and 7 days afterward, then 6-week observation Publicly funded null trial; Ehrhardt (Original protocol and purchased product).
Bosnia and Herzegovina adult AAD prevention Bularen 250 mg twice daily; manufacturer-stated minimum 5 billion CFU per capsule 28 days Small 2026 positive trial; strain code and procurement not fully resolved; Kovacevic (Original intervention).
Polish pediatric AAD prevention 250 mg twice daily During antibiotic treatment Funding unresolved; not a home pediatric dosing guide; Kotowska (Original abstract, full paper unavailable).
Italian pediatric acute diarrhea Label-stated 5 billion live organisms per dose, twice daily 5 days Purchased historical product; null yeast-arm result; Canani (Original label-based exposure).
Older C. difficile adjunct trial 1 g/day with prescribed antibiotic treatment 4 weeks Commercially linked recurrence research; McFarland (Original abstract, full paper unavailable).
Pakistani IBS-D pilot 750 mg/day added to ispaghula husk 6 weeks Manufacturer grant; biological/QOL signal, not independent symptom benefit; Abbas (Original protocol and product grant).

Different viable counts, drying processes, storage histories and excipients can accompany the same milligram figure. Neither this table nor a product’s survival in laboratory acid tests establishes an optimal dose for a particular person (Preparation specifications; Trial protocol).

Animal and in vitro evidence excluded from benefit conclusions

Laboratory anti-Candida effects are often used to sell “cleanses.” A capric-acid study investigated fungal growth, adhesion and biofilm behavior, rather than treating patients with candidiasis. It received both public and Biocodex support. It cannot establish clinical eradication or justify replacing an antifungal. Murzyn 2010

The 2025 antibiotic-microbiome experiment also had Biocodex funding and company employees among the authors. Its host-independent experimental effects remain mechanistic evidence. They were excluded from the human benefit verdict. Study disclosures

The genome study is informative about identity and variation. A sequence comparison does not establish a clinical treatment outcome. Khatri 2017

Reported funding and financial limits

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

37 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

What the research money shows

Two useful independence checks involve actual purchases. The German trial bought its product through a hospital pharmacy; the Italian trial asked parents to buy assigned products. Commercial availability alone does not create sponsorship. Conversely, a university affiliation or a statement that a sponsor did not influence the results does not erase a manufacturer grant. The IBS trial papers provide examples of those grants. German disclosure, Italian disclosure, Korean disclosure, Pakistani disclosure

“Provided,” “manufactured” and “supplied” are not synonyms for donated. The 2026 Bularen report identifies a manufacturer-made placebo without saying whether it was purchased or contributed. Its funding status remains unresolved at that point. Unknown is neither independent nor evidence of wrongdoing (Actual placebo disclosure).

The safety literature also needs scrutiny. Rannikko’s study names state research financing and a Finnish Medical Foundation scholarship, with one author’s separate pharmaceutical relationships. The foundation derives support from donations and investment assets, and accepts company donations; the donors behind that particular scholarship were not traced. That is a residual gap, not a demonstrated yeast-maker payment. Regulatory and microbiological corroboration matter. Study disclosures, foundation history, foundation donor model

Companies, countries and backers

Biocodex’s 2024 annual report, published at a URL bearing “2025,” describes a French, family-owned pharmaceutical business with €634 million in group revenue and manufacturing operations in France and Morocco. Those are group-level facts; they do not identify the production country of every capsule sold under license. Exact family ownership percentages, ultimate beneficial owners and product-specific margins were not verified. Biocodex annual report

The report connects Biocodex with the Microbiota Institute and Microbiota Foundation. Foundation grant documents describe corporate-foundation funding while asserting scientific-committee independence. That separation of grant decisions can be meaningful, but the foundation’s name or nonprofit status does not make the source of its money independent of the business. No foundation funding is assumed for a trial unless documented. Corporate report, foundation grant terms

Kuhnil’s Korean product and research support are recorded in Choi’s paper. The Bularen paper names Abela Pharm in Serbia and Abela BiH as its Bosnia and Herzegovina distributor. Their full ownership chains were not verified. These are distinct commercial relationships, not evidence that one company controls the whole yeast category. Choi, Kovacevic

Sellers and distributors earn revenue from product sales; promotional education can increase demand. This is incentive analysis, not an allegation that any stated result was fabricated. The same exclusion standard applies to favorable and unfavorable commercially supported outcomes (Corporate business model; Documented research support).

Documented money map

Documented funding and ownership relationships for saccharomyces boulardii. The full equivalent text and linked sources appear in the article.
Documented funding relationships. Open the full-size map. The equivalent text below cites each relationship. Biocodex’s report states family ownership and a French headquarters; exact family stakes remain unknown. Corporate report; Biocodex trial support; Public funding and purchased product.

Plain-text version:

Clinical examples here span Europe, Asia and North America. Several heavily cited strain-specific publications have links to the same French business, so article count is not the same as a count of independent replications. Country of study, sponsor headquarters, manufacturing location and the jurisdiction regulating a product should remain separate (Germany; Italy; Pakistan; US original).

Regulatory status

United Kingdom and European Union

Status is product- and country-specific. France lists Ultra-Levure as an authorized medicine for adjunctive symptomatic diarrhea treatment alongside rehydration. That authorization does not make every retail supplement a licensed medicine, nor independently validate every marketing claim. The examined label itself distinguishes its authorized use from controlled-trial documentation for that particular product. French public medicine record

An EMA assessment report is sometimes presented as an EU-wide approval. Its proposed herbal monograph did not achieve the required majority because of disagreement over the yeast’s classification. This is separate from national marketing authorizations and from the EU safety contraindications. A UK consumer should verify the actual product’s regulatory category rather than assume that French or other European status transfers automatically. EMA assessment conclusion

EFSA’s I-1079 opinion concerns a food-health claim and strain substantiation, not a medicinal authorization. These regulatory pathways answer different questions. EFSA opinion

United States

Dietary supplements are not FDA-preapproved for safety and effectiveness in the way drugs are. A probiotic supplement, a nationally authorized medicine elsewhere, and an FDA-authorized treatment are different regulatory categories. A strain trademark or clinical publication should not be presented as FDA approval to prevent or treat C. difficile or IBS. FDA supplement guidance

Frequently asked questions

Is S. boulardii a bacterium?

It is a yeast within the S. cerevisiae lineage. Antibacterial and antifungal medicines are different issues for a live yeast; that distinction does not establish clinical benefit (Genomic taxonomy; Antifungal restriction).

Is CNCM I-745 the same as any S. boulardii supplement?

No. It is a specific strain designation. Evidence should follow the verified strain and complete preparation, not just a shared species name (Recorded strain identity; Strain-transfer limit).

Does it definitely prevent diarrhea with antibiotics?

No. Positive trials and meta-analyses make a benefit plausible, but the independent and recent evidence is inconsistent, with important formulation, setting and funding gaps (Positive pool; Null trial; Recent positive trial).

Does it prevent C. difficile coming back?

Older add-on trials contain encouraging subgroup findings, but they have commercial ties and limited independent replication. Current adult AGA advice does not recommend probiotics for initial or recurrent infection prevention (Older original abstract; Original subgroup; Current adult recommendation).

Does improving inflammatory markers mean it treats IBS?

Not necessarily. The IBS studies illustrate why laboratory, quality-of-life and bowel-symptom outcomes must be reported separately (QOL primary versus symptoms; Biological/clinical outcomes).

Can it permanently repopulate the gut?

The examined product information describes transient passage rather than persistent colonization. That is not evidence of a permanent microbiome reset (Transient pharmacokinetics).

Is it safe because it is sold without a prescription?

No product category guarantees safety for every person. Critical illness, immune suppression and central venous catheters are especially important exclusions for this live yeast (Contraindications).

Does the low benefit grade mean it cannot help anyone?

The strict financial-screen grade does not mean nobody can benefit. It means a dependable general benefit is not established by the limited financially screened evidence reviewed here. Positive results, uncertainty and vulnerable-patient precautions remain separate (Favorable context; Null trial; Safety precautions).

Sources and funding notes

Tier 1 indicates no identifiable relevant stake in the declarations and finite checks available here; Tier 2 indirect ties; Tier 3 interested professional relationships; Tier 4 maker/seller funding, affiliation or promotion; U unresolved financial terms. These are provisional editorial classifications, not comprehensive financial clearance. A–D grades concern provenance/accountability, not methodological certainty. A source can combine public grants with commercial support; a no-conflict declaration is reported rather than independently certified.

Source Funding, ownership, country and backers Tier / provenance grade Accuracy incentive and remaining gap
Ehrhardt 2016 Germany/US academic authors; German ministry and institutional funds; product purchased; no conflicts reported 1 / A Prospective multicenter trial and explicit procurement; early stop/missing records limit inference (Original support/procurement).
Kovacevic 2026 Bosnia and Herzegovina/Serbia academics; no external funds/conflicts declared; Abela-made placebo, terms unknown U / B provisional Original methods/results are inspectable; no prospective registration, small trial and extreme comparator rate (Original financial/protocol declarations).
Szajewska 2015 Medical University of Warsaw funding; HS declared Biocodex speaking; constituent trial funding not fully traced 3 / B; underlying pool unresolved Full relevant review main/disclosures read; supplements and all constituent finance not audited
Kotowska 2005 Polish academic affiliations; complete original finance and procurement unavailable U / B provisional Original abstract read; full original Methods, numerical tables and declarations unavailable
Guo 2019 Cochrane review Indexed support text names Hospital for Sick Kids Foundation and no known author interests; full current table/declarations and donor chain not recovered U / B provisional Primary indexed sections only; complete Kotowska study table and constituent original finance not certified
Cochrane 2025 update Current primary abstract states no funding for update; 28 constituent trials had industry funding or affiliations U / B provisional Current original abstract and public summary read; complete final main tables/individual declarations inaccessible; public page mixes dated totals (Current original abstract).
Cochrane Canada funding page Undated historical page lists public/professional support, publishing royalties and varied entity finance U / B for historical model Institutional self-disclosure read; not proof of current central royalty mix or independence of a specific 2025 review
McFarland 1994 Original author affiliation includes Biocodex Seattle; complete historical budget/product terms inaccessible 4 / C Primary abstract and affiliation read; full original Methods/tables/disclosures unavailable
Surawicz 2000 original relevant report US centers; Biocodex affiliation, Laboratoires Biocodex France grant; company randomized and packaged blinded products 4 / C Original relevant methods/results/support read through author-sharing host; all final main/COI and exact supply terms not recovered. Small subgroup; antibiotics not randomly assigned Technical-review appraisal
AGA 2020 guideline AGA-developed guidance; Bercik Nestex/Allergan/IMHealthScience/Lupin, Weizman AbbVie/Janssen/Takeda/Ferring; specific budget unreported 3 / C Original relevant recommendations and disclosures read; underlying finance and complete individual forms not cleared
AGA 2020 technical review US society; authors disclose Novome, Otsuka, Pendulum, AbbVie, Ferring and other ties 3 / C Transparent methods; expert judgments and related-market interests (Original Methods/funding/conflicts).
AGA 2026 expert update AGA-commissioned; Fischer/Kelly/Vaughn commercial and OpenBiome interests; Peery no relevant COI 3 / C Primary abstract and indexed conflict paragraph read; complete final Methods/body/forms unavailable; expert review without formal GRADE
Canani 2007, full paper Italy; no funding/conflicts declared; parents purchased products; university authors 1 / B Real-world randomized comparison; single-blind design and unverified product contents (Actual original disclosures).
McFarland and Li 2025 US/China authors; Biocodex France research/publication funds and consultant/advisory interests 4 / C Full relevant original review read; all constituent trials unblinded/no placebo; underlying original finance and supplements unverified
WHO 2024 guideline; Recommendation text WHO general dues/voluntary model separately read; guideline-specific donors/individual declarations unavailable U / B provisional Original recommendation text and overview accessible; complete guideline methods/financial annexes not recovered
WHO financing Switzerland/global; member dues, governments, foundations and private-sector contributions 2 / A for finance model Official disclosure; donor priorities and earmarking do not establish a particular conclusion was purchased (Actual general finance model).
Preechakawin 2026 Thailand; no cash funding declared; drugs supported by DKSH Thailand and Farmaline 4 / C Original trial with explicit support disclosure; small sample and death exclusion (Actual product-support statement).
Choi 2011 full main; Primary record Kuhnil partly funded Korean trial; exact product purchase/donation terms unstated; commercial Caldic mirror 4 / C Full relevant original main read: 90 randomized, 67 efficacy completers; primary QOL positive, secondary symptoms null
Abbas 2014 full main; Primary record Biocodex France grant plus supplied yeast/matching placebo; supply payment/donation terms unstated 4 / C Full relevant original main/declarations read; 72 randomized, 64 completed, arbitrary sample, no overall bowel-symptom advantage
Rannikko 2021 Finland; state financing and Finnish Medical Foundation scholarship; Hohenthal reports GSK/Grifols/MSD ties; US CDC journal host 2 / B Clinical records and transparent disclosures; no exposure denominator or strain matching; grant donors not fully traced (Actual original declarations).
Finnish Medical Foundation history, donor model Finland; founded by Duodecim, donations and invested assets; private and company donors 2 / B Accountable grant-making; donor-level allocation to the safety scholarship unverified (Foundation history; Private/company donations).
Roy 2017 original relevant sections; Primary metadata India Apollo/PGIMER; ICMR supported typing/susceptibility; separate COI and product terms unreported U / B provisional Actual original relevant Methods/Results/acknowledgment read; tiny local cohort cannot establish general consumer incidence
EU pharmacovigilance action EU regulatory network; EMA headquartered in Netherlands; public and regulated-industry fees 2 / A for safety action Legal accountability and cross-case review; reporting rates are not exact incidence (Original safety action; Current agency revenue).
Belgian FAMHP notice Belgian government regulator; detailed agency financing and notice-specific costs not traced 2 / A for warning National pharmacovigilance mandate; largely relays the same EU action (Original Belgian warning).
EMA 2021 assessment; 2026 budget forecast Official EU agency public/regulated-service fee financing; original assessment received manufacturer submissions 2 / A for finite regulatory facts Specified main assessment and budget sections read; not every constituent trial/disclosure or report-specific budget verified
EFSA 2012 I-1079 opinion; 2026 draft revenues Commission-requested opinion; 2026 draft budget mainly EU/third-country contributions; historic individual panel finances not reconstructed U / A for claim scope Full relevant opinion reasoning and draft revenue page read; draft budget is not 2012 panel independence clearance
French Ultra-Levure record France; Biocodex authorization-holder label on public government database 4 / C Regulated product accountability; label provenance remains commercial (Original commercial label).
Malta Bioflor label Malta regulator host; Biocodex France product information 4 / C Regulated identity/warnings; not independent efficacy confirmation (Original commercial label).
Khatri 2017 India; CSIR/DBT public grants; Unique Biotech supplied the Sb-unique28 sample, transaction terms unknown; no competing interests declared U / B provisional Reproducible genomic methods; no clinical outcomes; supplied sample is not assumed donated or independently purchased (Original sample/support declarations).
Murzyn 2010 Poland/Czech research; Biocodex plus public/institutional support 4 / C Inspectable laboratory methods; anti-Candida effects are not patient eradication evidence (Original maker/public support).
2025 host-independent experiment full original; Publisher record Biocodex grant/supplied yeast/employees plus regional/ANR public support and other author commercial ties 4 / C Full main original Methods/Results/disclosures read; donor systems/cells not patient treatment; no universal composition restoration
Biocodex 2024 annual report France; family-owned product-sales business; precise stakes unverified 4 / C for corporate facts Public corporate commitments; self-presentation and commercial incentive (Original corporate report).
2024 Nordic foundation grant terms Biocodex company nonprofit foundation; €40,000 institutional grant, company presentation/reporting rules; independent committee claimed 4 / C for actual grant terms All three pages read; decision separation is not money-source independence or a link to an unnamed trial
NHS sepsis guidance UK public-service clinical guidance; exact page-specific budget and author interests not reported U / A for clinical warning Complete relevant original warning/action sections read; general signs rather than yeast-specific incidence
NIDDK diarrhea guidance US NIH institutional education; page-specific cash and individual editorial finances not reported U / A for clinical warning Complete original relevant symptoms/referral sections read; no retail-product efficacy assessment
NIDDK bleeding guidance US NIH institutional education; page-specific cash and individual editorial finances not reported U / A for clinical warning Complete original relevant warning signs read; not a yeast-product efficacy or agency-budget assessment
FDA supplement guidance US federal regulator; this linked guidance supplies no page-specific budget or individual reviewer financial statement U / A for legal scope Original relevant regulatory sections read; agency hosting does not establish product benefit or comprehensive financial independence

The linked Cochrane Canada page describes a historical publishing/support model; WHO’s current page describes assessed and voluntary funds; EMA’s 2026 forecast includes substantial service fees and public contributions. These finite institutional accounts do not establish who paid for each trial, every individual’s interests, or control over a particular conclusion (Historical Cochrane page; WHO model; EMA forecast).

Scope: focused review of the sources cited here for AAD, CDI prevention/recurrence, acute diarrhea, IBS, strain identity and important safety. Complete original papers remained unavailable for Kotowska 2005, McFarland 1994, the 2025 CDAD review and 2026 AGA update; WHO/Guo 2019 access was partial. Their limits are identified at the relevant claims. Full underlying trial finance, private procurement, historical individual disclosures and ultimate ownership were not exhaustively reconstructed. This is not a catalog of every product or indication.

Last reviewed: 1 October 2026.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.